Logo 1 Logo 2

Investigational Drug Details

Drug ID: D285
Drug Name: Edetic acid
Synonyms:
Type: small molecule
DrugBank ID: DB00974
DrugBank Description: A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
PubChem ID: 6049
CasNo: 60-00-4
Repositioning for NAFLD: Yes
SMILES: OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
Structure:
InChiKey: KCXVZYZYPLLWCC-UHFFFAOYSA-N
Molecular Weight: 292.2426
DrugBank Targets: Lead; Iron; Manganese cation
DrugBank MoA: The pharmacologic effects of edetate calcium disodium are due to the formation of chelates with divalent and trivalent metals. A stable chelate will form with any metal that has the ability to displace calcium from the molecule, a feature shared by lead, zinc, cadmium, manganese, iron and mercury. The amounts of manganese and iron metabolized are not significant. Copper is not mobilized and mercury is unavailable for chelation because it is too tightly bound to body ligands or it is stored in inaccessible body compartments. The excretion of calcium by the body is not increased following intravenous administration of edetate calcium disodium, but the excretion of zinc is considerably increased.
DrugBank Pharmacology: Edetate calcium is a heavy metal chelating agent. The calcium in edetate calcium can be displaced by divalent or trivalent metals to form a stable water soluble complex that can be excreted in the urine. In theory, 1 g of edetate calcium can theoretically bind 620 mg of lead, but in reality only about 5 mg per gram is actually excreted into the urine in lead poisoned patients. In addition to chelating lead, edetate calcium also chelates and eliminates zinc from the body. Edetate calcium also binds cadmium, copper, iron and manganese, but to a much lesser extent than either lead or zinc. Edetate calcium is relatively ineffective for use in treating mercury, gold or arsenic poisoning.
DrugBank Indication: For the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
Targets:
Therapeutic Category:
Clinical Trial Progress:
Latest Progress: